箕星是一家总部位于中国上海的生物制药公司，致力于将创新科学和药物带给罹患严重危及生命健康疾病的中国患者。箕星由RTW Investments, LP于2019年投资创立，与全球多家生物技术公司开展合作，通过开发和商业化独特创新的治疗药物，应对心血管和眼科疾病领域尚未满足的医疗需求。凭借强劲且不断壮大的产品管线、经验丰富的管理团队和以患者为中心的理念，箕星将为大中华地区的患者群体带来持久而深远的影响。<\/p> \n

Milestone Pharmaceuticals（纳斯达克股票代码：MIST）是一家专注于心血管创新药物开发及商业化的生物制药公司。Milestone的主要在研产品etripamil目前正处于治疗阵发性室上性心动过速(PSVT) 的 3 期临床阶段和治疗快速心室率房颤（ AFib-RVR ）患者的 2 期概念验证试验。Milestone Pharmaceuticals在加拿大和美国开展业务。如需了解更多信息，请访问www.milestonepharma.com<\/a>。<\/p> \n

\n \n \n \n \n \n \n \n
参考文献<\/i><\/span><\/p> <\/td> \n <\/tr> \n
1.    <\/i>Chiang JK, Kao HH, Kao YH. Association of Paroxysmal Supraventricular Tachycardia with Ischemic Stroke: A National Case-Control Study. <\/i>Journal of Stroke and Cerebrovascular Diseases (2017); 26(7):1493-1499.<\/i><\/span><\/p> <\/td> \n <\/tr> \n
2. <\/i>Chan CL, Li AA, Chung HA, Phan DV. Cost Effectiveness Analysis and Payment Policy Recommendation-Population-Based Survey with Big Data Methodology for Readmission Prevention of Patients with Paroxysmal Supraventricular Tachycardia treated with Radiofrequency Catheter Ablation. <\/i>International Journal of Environmental Research and Public Health (2020); 17(7):2334.<\/i><\/span><\/p> <\/td> \n <\/tr> \n
3.    <\/i>Ho HH, Yeh SJ, Tsai WP, et al. Paroxysmal supraventricular tachycardia and Wolff-Parkinson-White syndrome in ankylosing spondylitis: a large cohort observation study and literature review. <\/i>Seminars in Arthritis and Rheumatism (2012); 42(3):246-53.<\/i><\/span><\/p> <\/td> \n <\/tr> \n
4.   <\/i>Orejarena LA, Vidaillet H Jr, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. <\/i>Journal of the American College of Cardiology (1998); 31(1):150-7. <\/i><\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p> \n
媒体联络<\/i><\/p> \n
箕星药业
<\/i>media@jixingbio.com<\/a><\/i> <\/p>"]; $("#dvExtra").html(content_array[0]);})();